Payment overview · 2025
General Payments
$105.35
5 reported records · 4 companies
Healthcare provider profile · identity verified
Jonathan A Borchard, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · BLOOM, KS · NPI 1578650834
Verified facts
What the public records show
CMS Open Payments records show Jonathan A Borchard, PAC received $105.35 in general payments during 2025 across 5 reported records.
CSL Behring accounted for 33.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CSL Behring | Unresolved — no canonical attribution shown | $34.98 | 33.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.37 | 28.8% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $22.69 | 21.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.31 | 16.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $105.35 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Andembry Normalized: andembry |
Biological | CSL Behring | $34.98 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 391 | 87 |
| Omeprazole | Omeprazole | 333 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 259 | 62 |
| Eliquis | Apixaban | 243 | 24 |
| Potassium Chloride | Potassium Chloride | 224 | 61 |
| Furosemide | Furosemide | 194 | 53 |
| Losartan Potassium | Losartan Potassium | 179 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 178 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 178 | 51 |
| Lisinopril | Lisinopril | 173 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 170 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 37 |
| Gabapentin | Gabapentin | 129 | 34 |
| Allopurinol | Allopurinol | 126 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 21 |
| Tramadol Hcl | Tramadol Hcl | 119 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 113 | suppressed |
| Alprazolam | Alprazolam | 103 | 24 |
| Trazodone Hcl | Trazodone Hcl | 97 | 23 |
| Finasteride | Finasteride | 93 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 91 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 25 |
| Glimepiride | Glimepiride | 88 | 23 |
| Metformin Hcl | Metformin Hcl | 87 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 25 |
| Warfarin Sodium | Warfarin Sodium | 86 | 14 |
| Famotidine | Famotidine | 85 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 23 |
| Simvastatin | Simvastatin | 71 | 19 |
| Donepezil Hcl | Donepezil Hcl | 67 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 13 |
| Carvedilol | Carvedilol | 60 | 14 |
| Xarelto | Rivaroxaban | 60 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 59 | 12 |
| Celecoxib | Celecoxib | 55 | 15 |
| Ezetimibe | Ezetimibe | 55 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 11 |
| Lorazepam | Lorazepam | 53 | suppressed |
| Sucralfate | Sucralfate | 53 | 17 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 50 | suppressed |
| Bumetanide | Bumetanide | 50 | suppressed |
| Pregabalin | Pregabalin | 48 | 11 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 44 | 14 |
| Ozempic | Semaglutide | 44 | suppressed |
| Spironolactone | Spironolactone | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Azithromycin | Azithromycin | 39 | 23 |
| Rybelsus | Semaglutide | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 22 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | 27 |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | 11 |
| Atenolol | Atenolol | 25 | suppressed |
| Nystatin | Nystatin | 25 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Pulmicort Flexhaler | Budesonide | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $105.35 · 5 records | CSL Behring | AIRSUPRA, Andembry, BREZTRI, EOHILIA, EVENITY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error